Project Grant HT9425261E396
Award Date 9/16/26
Completion Date 9/14/29
Dollars Obligated $1.4M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded MD Anderson Cancer Center a $560K Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2026, through August 31, 2028. The award supports research on modulating hypoxia-activated stromal programs to potentiate chimeric antigen receptor T (CAR-T) cell therapy in kidney cancer. This project directly aligns with the DHA's mission to advance biomedical solutions for Service...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded MD Anderson Cancer Center a Project Grant of $559,463 under the Military Medical Research and Development program (CFDA 12.420) for the period August 1, 2026 through July 31, 2028. The award supports research investigating "Alternating Clonal Dominance and Local Microenvironment Evolution at the Primary Tumor Site as Key Drivers of Metastatic Dissemination in Pancreatic Cancer." This research addresses...
- Federal Grant Award Summary Award Details: The Defense Health Agency (DHA) awarded a $1,099,986 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The University of Texas MD Anderson Cancer Center for the period June 1, 2026, through May 31, 2030. The project, titled "Metabolic Rewiring of CAR-T Cells to Counter the Hostile Tumor Microenvironment in Pancreatic Cancer," will be conducted at MD Anderson's Houston, Texas facility. Research Scope:...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded a $1.25 million Project Grant to MD Anderson Cancer Center on July 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to support research on novel cholesterol-targeting therapies for inflammatory breast cancer. The three-year award, with an ultimate completion date of June 30, 2029, funds investigator-initiated biomedical research aimed at developing innovative therapeutic approaches...
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $1.35 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the three-year period from October 1, 2025, through September 30, 2028. The award funds research focused on building T-cell products for neurofibromatosis type 1 (NF1)-associated malignant peripheral nerve sheath tumors (MPNST) through antigen discovery and...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded The University of Texas MD Anderson Cancer Center a $1.398 million Project Grant under the Military Medical Research and Development program (CFDA 12.420) on June 1, 2026, for the three-year project "Combined PAN and Precision Targeting in Extrachromosomal DNA-Positive Gastric Cancer," with completion expected by May 31, 2029. This award supports investigator-initiated biomedical research addressing cancer therapeutics...
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $490,500 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), effective September 1, 2025, through August 31, 2028. The grant funds research combining TROP2-directed chimeric antigen receptor natural killer (CAR-NK) cells with HIF2A (hypoxia-inducible factor 2-alpha) inhibition to develop novel immunotherapy approaches for pancreatic...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $735,751 project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective September 1, 2025, through August 31, 2028. The award supports research and development activities focused on combining TROP2-directed chimeric antigen receptor natural killer (CAR-NK) cells with HIF2A (hypoxia-inducible factor 2-alpha) inhibition as an...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded $414,472 to The University of Texas MD Anderson Cancer Center under the Military Medical Research and Development program (CFDA 12.420) for the project "Targeting Neuronal Mimicry in SMARCB1-Deficient Renal Medullary Carcinoma Treatment." The three-year award, effective September 1, 2025 through August 31, 2028, supports investigator-initiated biomedical research addressing cancer treatment solutions relevant...
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $559,576 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective July 1, 2026, through June 30, 2029. This award supports research investigating desmoplastic small round cell tumors (DSRCTs), with specific focus on tumor plasticity and resistance mechanisms to improve therapeutic outcomes. The three-year project will be...